discovery chemistry
ADC – Different Linker Synthesis Experience
We have the capabilities to design and synthesise novel ADC linkers and linker–payload architectures
In recent years, we have continued to strengthen and expand our ADC discovery capabilities, supporting multiple client programs across linker design, payload chemistry, and conjugation technologies. Our
Examples of payloads we have worked with include:
growing expertise enables the development of complex ADC components from early-stage design through synthesis and characterization.
Design and synthesis of cleavable and non-cleavable linkers (Val-Cit, Val-Ala, disulfide, List of cleavable ADC Linkers – easy access of these linkers glucuronide, PEG, click chemistry, and maleimide/NHS ester), utilizing SPPS technology for the rapid synthesis, customization, and delivery of peptide-based linker libraries.
Development of linker-payload constructs and conjugation-ready building blocks.
Experience with a diverse range of payloads, including Exatecan, SN38, MMAE, PBD dimers, BCN-PEG-Val-Cit-
Elimusertib, steroidal and non-steroidal payloads, and other potent anticancer heterocyclic
Design of peptide linker–payload conjugates to improve tumor-selective payload release and Clickable linkers minimize off-target exposure.
Development of Targeted Drug Conjugates (TDCs) incorporating SR48692-derived targeting cadaverine-Val-Citligands (receptor-targeting small molecules) and A1331852-derived payloads (potent apoptosis-
PABC- Paylaod
GGFG-linker inducing small-molecule payloads), integrated with optimized linker technologies for selective
PeLtide linker drug delivery.
Route scouting, optimization, purification (Prep HPLC/flash chromatography), and MC-A-B-C-Citcomprehensive analytical characterization (LC-MS, HRMS, NMR, HPLC, and chiral SFC).
By combining expertise in medicinal chemistry, peptide synthesis, and analytical sciences, we provide integrated support for ADC discovery—from custom linker synthesis to complex linker-payload development—helping accelerate next-generation targeted therapeutics.